Was tumour necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s?

Medical Hypotheses

Volumn 50, Issue 4, 1998, Pages 313-318

  Argiles J M ^a   Carbo N ^a   Lopez Soriano F J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SEDATIVE AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG MECHANISM; EMBRYO DEVELOPMENT; ENDOMETRIUM; EXPERIMENTAL ANIMAL; FETUS; FETUS MALFORMATION; HUMAN; PLACENTA; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0031776079     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90003-2     Document Type: Article

References (66)

1. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203-215.
2. Hellmann K, Duke D I, Tucker D F. Prolongation of skin homograft survival by thalidomide. Br Med J 1965; 18: 687-689.
3. Coley W B. The treatment of malignant tumours by repeated inoculations of erysipelas; with a report of ten original cases. Am J Med Sci 1893; 105: 487-511.
4. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-632.
5. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981; 154: 631-637.
6. Beutler B, Greenwald D, Hulmes J D et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552-554.
7. Jue D M, Sherry B, Luedke C, Manogue K R, Cerami A. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 1990; 29: 8371-8377.
8. Aggarwal B B, Natarajan K. Tumor necrosis factors: developments during last decade. Eur Cytokin Netw 1996; 7: 93-124.
9. Sampaio E P, Sarno E N, Galilly R J, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-α production in stimulated human monocytes. J Exp Med 1991; 173: 699-703.
10. Sampaio E P, Kaplan G, Miranda A et al. The influence of thalidomide on the clinical and immunological manifestation of erithema nodosum leprosum. J Infect Dis 1993; 168: 408-414.
11. Moreira AL, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-a by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
12. Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol-esther induced production of tumour necrosis factor-α by thalidomide. Biochim Biophys Res Commun 1994; 199: 455-460.
13. Shannon EJ, Sandoval F. Thalidomide can be either either agonistic or antagonistic to LPL evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol Immunotoxicol 1996; 18: 59-72.
14. Ching L M, Zu Z F, Gummer B H, Palmer B D, Joseph B R, Baguley B C. Effects of thalidomide on tumor necrosis factor production and anti-tumour activity induced by 5,6-dimethyl-xantenone-4-acetic acid. Br J Cancer 1995; 72: 339-343.
15. Netea N G, Block W L, Kullberg B G et al. Pharmacological inhibitors of tumour necrosis factor production exert differential effects in endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171: 393-399.
16. Silver R M, Lohner W S, Daynes R A, Mitchell M D, Branch D W. Lipopolysaccharide-induced fetal death: the role of tumor-necrosis factor alpha. Biol Reprod 1994; 50: 1108-1112.
17. Roby K F, Weed J, Lyles R, Terranova P F. Immunological evidence for a human ovarian tumor necrosis factor-α. J Clin Endocrinol Metab 1990; 71: 1096-1102.
18. Tabibzadeh S. Ubiquitous expression of TNF-α/cachectin in human endometrium. Am J Rep Immunol 1991; 26: 1-5.
19. Hunt J S, Chen H L, Hu X L, Tabibzadeh S. Tumor necrosis factor-α mRNA and protein in human endometrium. Hum Biol Reprod 1992; 47: 141-147.
20. Yelavarthi K K, Chen H L, Yang Y, Fishback J L, Cowley B D, Hunt J S. Tumor necrosis factor-alpha mRNA and protein in rat uterine and placental cells. J Immunol 1991; 146: 3840-3848.
21. Hunt J S, Chen H L, Hu X , Pollard J W. Normal distribution of tumor necrosis factor-α messenger ribonucleic acid and protein in virgin and pregnant osteopetrotic (op/op) mice. Biol Reprod 1993; 49: 441-452.
22. Casey M L, Cox S M, Beutler B, Milewitch L, MacDonald P C. Cachectin/tumor necrosis factor-α formation in human decidua: potential role of cytokines in infection induced preterm labor. J Clin Invest 1989; 83: 430-436.
23. Zolti M, Ben-Rafael Z, Meirom R et al. Cytokine involvement in oocytes and early embryos. Fertil Steril 1991; 56: 265-272.
24. Opsjon S L, Wathen N C, Tingulstad S et al. Tumor necrosis factor, interleukin-1, and interleukin-6 in normal human pregnancy. Am J Obstet Gynecol 1993; 169: 397-404.
25. Giudice L C. Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 1994; 61: 1-17.
26. Tartakovski B, Ben-Yair E. Cytokines modulate preimplantation development and pregnancy. Develop Biol 1991; 146: 345-352.
27. Eisermann J, Register K B, Strickler R C, Collins J L. The effect of tumor necrosis factor on human sperm motility in vitro. J Androl 1989; 10: 270-274.
28. Hill J A, Haimovici F, Politch J A, Anderson D J. Effects of soluble products of activated lymphocytes and macrophages (lymphokines and monokines) on human sperm motion parameters. Fertil Steril 1987; 47: 460-465.
29. Hill J A, Haimovici F, Anderson D J. Products of activated-T lymphocytes and macrophages inhibit mouse embryo development in vitro. J Immunol 1987; 139: 2250-2254.
30. Wincek T J, Meyer T K, Meyer M R, Kuehl J J. Absence of a direct effect of recombinant tumor necrosis factor-alpha on human sperm function and murine preimplantation development. Fertil Steril 1991; 56: 332-339.
31. Pampfer S, Vanderheyden I, Dam D, De Hertogh R. Increased TNF-α synthesis in the uterus of the diabetic pregnant rat. Eur Cytokine Netw 1996; 7: 269.
32. Pampfer S, Vanderheyden I, Wuu Y D, Baufays L, Maillet O, De Hertogh R. A possible role of tumor necrosis factor-α in the early embryopathy associated with maternal diabetes in the rat. Diabetes 1995; 44: 531-536.
33. Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
34. Romero R, Manogue K R, Mitchell M D. Infection and labor, IV: Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol 1989; 161: 336-341.
35. Lachapelle M H, Miron P, Hemmings R et al. Embryonic resistance to tumour necrosis factor-α mediated cytotoxicity: novel mechanism underlying maternal immunological tolerance to the fetal allograft. Human Reprod 1993; 8: 1032-1038.
36. H2 phenomenon? Immunol Today 1993; 14: 353-356.
37. Chen H L, Yang Y P, Hu X L, Yelavarthi K K, Fishback J L, Hunt J S. Tumor necrosis factor-α messenger RNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 1991; 139: 327-335.
38. Austgulen R, Liabakk N B, Brockhaus M, Espevick T. Soluble TNF receptors in amniotic fluid and in urine of pregnant women. J Reprod Immunol 1992; 22: 105-116.
39. Kaira P S, Sahu A, Kalra S P. Interleukin-1 inhibits the ovarian steroid induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats. Endocrinology 1990; 126: 2145-2152.
40. Koike K, Masumoto N, Kasahara K et al. Tumor necrosis factor-alpha stimulates prolactin release from anterior pituitary cells: a possible involvement of intracellular calcium mobilization. Endocrinology 1991; 128: 2785-2790.
41. Jikihara H, Handwerger S. Tumor necrosis factor-α inhibits the synthesis and release of human decidual prolactin. Endocrinology 1994; 134: 353-357.
42. Jaattela M, Kuusela P, Saksela E. Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest 1988; 58: 48-52.
43. Golander A, Hurley T, Barret J, Hizi A, Handwerger S. Prolactin synthesis by human chorion-decidual tissue: a possible source of prolactin in the amniotic fluid. Science 1978; 202: 311-313.
44. Ohashi K, Saji K, Kato M, Wakimoto A, Tanizawa O. Tumor necrosis factor-α inhibits human chorionic gonadotropin secretion. J Clin Endocrinol Metab 1992; 74: 130-134.
45. Li Y, Matsuzaki N, Masuhiro K et al. Trophoblast-derived tumor necrosis factor-α induces release of human chorionic gonadotropin using interleukin-6 (IL-6) and IL-6-receptor-dependent system in the normal human trophoblasts. J Clin Endocrinol Metab 1992; 74: 184-191.
46. Yamaguchi M, Ogren L, Barnard R et al. Selective inhibition of mouse placental lactogen II secretion by tumour necrosis factor-alpha. J Endocrinol 1994; 143: 95-105.
47. Tabibzadeh S. Human endometrium: an active site of cytokine production and action. Endocrine Rev 1991; 2: 272-290.
48. Yan Z, Hunter V, Weed J, Hutchinson S, Terranova P. Tumor necrosis factor-α alters steroidogenesis and stimulates proliferation of human ovarian granulosal cells in vitro. Fertil Steril 1993; 59: 332-338.
49. Roby K F, Hunt J S. Mouse endometrial tumor necrosis factor-α mRNA and protein: localization and regulation by estradiol and progesterone. Endocrinology 1994; 135: 2780-2789.
50. Hillier S L, Witkin S S, Krohn M A, Watts D H, Kiviat N B, Eschenbach D A. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. Obstet Gynecol 1993; 81: 941-948.
51. Zahl P A, Bjerknes C. Induction of decidua-placental hemorrhage in mice by the endotoxins in certain gram-negative bacteria. Proc Soc Exp Biol Med 1943; 54: 329-335.
52. Kass E H. Effect of corticosteroids and of hormones of pregnancy on the lethal action of bacterial endotoxins. Ann NY Acad Sci 1960; 88: 107-115.
53. Laham N, Brennecke S P, Bendtzen K, Rice G E. Tumour necrosis factor-α during pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. Eur J Endocrinol 1994; 131: 607-614.
54. Quinn P A, Butany J, Taylor J, Hannah W. Chorioamnionitis: its association with pregnancy outcome and microbial infection. Am J Obstet Gynecol 1987; 156: 379-387.
55. Hillier S L, Martius J, Krohn M, Kiviat N, Holmes K K, Eschenbach D A. A case-control study of chorioamniotic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319: 972-978.
56. Romero R, Roslansky P, Oyarzun E et al. Labor and infection, II: Bacterial endotoxin in amniotic fluid and its relationship to the onset of preterm labor. Am J Obstet Gynecol 1988; 158: 1044-1049.
57. Waltman R, Tricomi V, Palav A B. Mid-trimester hypertonic saline induced abortion: effect of indomethacin on induction/ abortion time. Am J Obstet Gynecol 1972; 114: 829-831.
58. Keirse M J N C, Grandi A, King J F. Preterm labour. In: Chambers I, Enkin M, Keirse M J N C, eds. Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1989: 829-831.
59. 2 on motility of the pregnant human uterus. Am J Obstet Gynecol 1968; 102: 317-326.
60. Vogelsang C B, Farmer E R, Hess A D et al. Thalidomide for the treatment of graft-versus-host disease. N Engl J Med 1992; 326: 1055-1058.
61. Revuz J, Guilaaume J C, Janier M et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126: 923-927.
62. Burrows N P, Walport N J, Hammond A H, Davey N, Jones R R. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 1991; 125: 62-67.
63. Larsson H. Treatment of severe colitis in Behcet's syndrome with thalidomide (BG-217). J Intern Med 1990; 218: 405-407.
64. Ostraat O, Ekberg H, Schatz H, Riesbek K, Eriksson T. Thalidomide prolongs graft survival in rat cardiac transplants. Transplant Proc 1992; 24: 2624-2625.
65. Makonkawkeyoon S, Limson-Pobre R N R, Moreira A L, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type I. Proc Natl Acad Sci USA 1993; 90: 5974-5978.
66. Pallarés-Trujillo J, López-Soriano F J, Argilés J M. TNF and AIDS: two sides of the same coin? Med Res Rev 1995; 15: 533-546.